BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 25976766)

  • 1. Synthesis and Evaluation of a Novel Deguelin Derivative, L80, which Disrupts ATP Binding to the C-terminal Domain of Heat Shock Protein 90.
    Lee SC; Min HY; Choi H; Kim HS; Kim KC; Park SJ; Seong MA; Seo JH; Park HJ; Suh YG; Kim KW; Hong HS; Kim H; Lee MY; Lee J; Lee HY
    Mol Pharmacol; 2015 Aug; 88(2):245-55. PubMed ID: 25976766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and biological evaluation of novel deguelin-based heat shock protein 90 (HSP90) inhibitors targeting proliferation and angiogenesis.
    Chang DJ; An H; Kim KS; Kim HH; Jung J; Lee JM; Kim NJ; Han YT; Yun H; Lee S; Lee G; Lee S; Lee JS; Cha JH; Park JH; Park JW; Lee SC; Kim SG; Kim JH; Lee HY; Kim KW; Suh YG
    J Med Chem; 2012 Dec; 55(24):10863-84. PubMed ID: 23186287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological evaluation of C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors.
    Kim HS; Hong M; Ann J; Yoon S; Nguyen CT; Lee SC; Lee HY; Suh YG; Seo JH; Choi H; Kim JY; Kim KW; Kim J; Kim YM; Park SJ; Park HJ; Lee J
    Bioorg Med Chem; 2016 Nov; 24(22):6082-6093. PubMed ID: 27745993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a novel Hsp90 inhibitor NCT-50 as a potential anticancer agent for the treatment of non-small cell lung cancer.
    Hyun SY; Le HT; Nguyen CT; Yong YS; Boo HJ; Lee HJ; Lee JS; Min HY; Ann J; Chen J; Park HJ; Lee J; Lee HY
    Sci Rep; 2018 Sep; 8(1):13924. PubMed ID: 30224681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ring-truncated deguelin derivatives as potent Hypoxia Inducible Factor-1α (HIF-1α) inhibitors.
    Kim HS; Hong M; Lee SC; Lee HY; Suh YG; Oh DC; Seo JH; Choi H; Kim JY; Kim KW; Kim JH; Kim J; Kim YM; Park SJ; Park HJ; Lee J
    Eur J Med Chem; 2015 Nov; 104():157-64. PubMed ID: 26457742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis for depletion of heat shock protein 90 client proteins by deguelin.
    Oh SH; Woo JK; Yazici YD; Myers JN; Kim WY; Jin Q; Hong SS; Park HJ; Suh YG; Kim KW; Hong WK; Lee HY
    J Natl Cancer Inst; 2007 Jun; 99(12):949-61. PubMed ID: 17565155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel C-terminal heat shock protein 90 inhibitor that overcomes STAT3-Wnt-β-catenin signaling-mediated drug resistance and adverse effects.
    Lee HJ; Min HY; Yong YS; Ann J; Nguyen CT; La MT; Hyun SY; Le HT; Kim H; Kwon H; Nam G; Park HJ; Lee J; Lee HY
    Theranostics; 2022; 12(1):105-125. PubMed ID: 34987637
    [No Abstract]   [Full Text] [Related]  

  • 8. C-terminal HSP90 inhibitor L80 elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition.
    Cho TM; Kim JY; Kim YJ; Sung D; Oh E; Jang S; Farrand L; Hoang VH; Nguyen CT; Ann J; Lee J; Seo JH
    Cancer Lett; 2019 Apr; 447():141-153. PubMed ID: 30703411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of B,C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors for use as anti-breast cancer agents.
    Kim HS; Hoang VH; Hong M; Chul Kim K; Ann J; Nguyen CT; Seo JH; Choi H; Yong Kim J; Kim KW; Sub Byun W; Lee S; Lee S; Suh YG; Chen J; Park HJ; Cho TM; Kim JY; Seo JH; Lee J
    Bioorg Med Chem; 2019 Apr; 27(7):1370-1381. PubMed ID: 30827868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor Suppression Efficacy of Heat Shock Protein 90 Inhibitor 17AAG in a Liposarcoma Mouse Model.
    Nam S; Kim H; Hong D; Park JB; Kim SJ
    Anticancer Res; 2017 Nov; 37(11):6291-6302. PubMed ID: 29061812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis.
    Acquaviva J; He S; Sang J; Smith DL; Sequeira M; Zhang C; Bates RC; Proia DA
    Mol Cancer Res; 2014 May; 12(5):703-13. PubMed ID: 24554781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of novel antiangiogenic anticancer activities of deguelin targeting hypoxia-inducible factor-1 alpha.
    Oh SH; Woo JK; Jin Q; Kang HJ; Jeong JW; Kim KW; Hong WK; Lee HY
    Int J Cancer; 2008 Jan; 122(1):5-14. PubMed ID: 17764071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a simplified deguelin analog as an HSP90 C-terminal inhibitor for HER2-positive breast cancer.
    Nguyen CT; Thanh La M; Ann J; Nam G; Park HJ; Min Park J; Kim YJ; Young Kim J; Hong Seo J; Lee J
    Bioorg Med Chem Lett; 2021 Aug; 45():128134. PubMed ID: 34044120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-tumor selectivity of a novel tubulin and HSP90 dual-targeting inhibitor in non-small cell lung cancer models.
    Zhang Q; Zhai S; Li L; Li X; Zhou H; Liu A; Su G; Mu Q; Du Y; Yan B
    Biochem Pharmacol; 2013 Aug; 86(3):351-60. PubMed ID: 23743233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1α and induces G2/M arrest under hypoxia in prostate cancer cells.
    Manohar SM; Padgaonkar AA; Jalota-Badhwar A; Rao SV; Joshi KS
    Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):15-27. PubMed ID: 22083267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
    Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
    Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A group of novel HIF-1α inhibitors, glyceollins, blocks HIF-1α synthesis and decreases its stability via inhibition of the PI3K/AKT/mTOR pathway and Hsp90 binding.
    Lee SH; Jee JG; Bae JS; Liu KH; Lee YM
    J Cell Physiol; 2015 Apr; 230(4):853-62. PubMed ID: 25204544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and Evaluation of the Tumor Cell Growth Inhibitory Potential of New Putative HSP90 Inhibitors.
    Bizarro A; Sousa D; Lima RT; Musso L; Cincinelli R; Zuco V; De Cesare M; Dallavalle S; Vasconcelos MH
    Molecules; 2018 Feb; 23(2):. PubMed ID: 29438315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of hybrid Hsp90 inhibitors and their anti-neoplastic effects against gefitinib-resistant non-small cell lung cancer (NSCLC).
    Jeong CH; Park HB; Jang WJ; Jung SH; Seo YH
    Bioorg Med Chem Lett; 2014 Jan; 24(1):224-7. PubMed ID: 24345447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and biological evaluation of truncated deguelin derivatives as Hsp90 inhibitors.
    Yao H; Xu F; Wang G; Xie S; Li W; Yao H; Ma C; Zhu Z; Xu J; Xu S
    Eur J Med Chem; 2019 Apr; 167():485-498. PubMed ID: 30784881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.